<DOC>
	<DOCNO>NCT02960880</DOCNO>
	<brief_summary>The aim study ass real world comparative effectiveness Rivaroxaban prescribe non-valvular atrial fibrillation ( NVAF ) routine care patient Germany .</brief_summary>
	<brief_title>Real-world Comparative Effectiveness Stroke Prevention Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>First dispense date Rivaroxaban ( 15mg 20mg PZN base ) Phenprocoumon ( PZN base ) January 1 , 2012 December 31 , 2015 At least two verified outpatient diagnose one inpatient diagnosis ( main secondary diagnosis ) NVAF ( ICD10 GM I48.0/I48.1/I48.2/I48.9 ) individual time frame 4 quarter index date ( preindex period ) within index quarter Patients require 4 quarter enrollment assessment baseline characteristic observable insured database least one day individual index date ( postindex period ) â‰¥ 18 year age Patients valvular AF [ 4 quarter prior index date ] Pregnancy [ 4 quarter prior index date ] Malignant cancer [ 4 quarter prior index date `` condition '' ] Transient cause AF [ 4 quarter prior index date ] Patients VTE ( pulmonary embolism DVT ) [ 60 day index ] Patients major surgery define hip knee replacement [ 60 day index ] Prescriptions OACs ( Rivaroxaban , VKA , Dabigatran , Apixaban ) index date [ 4 quarter prior index date ] Patients receive one anticoagulant substance ( Apixaban , Dabigatran , Rivaroxaban Phenprocoumon ) one dosage substance index date For sensitivity analysis : Patient event define combined endpoint [ 4 quarter prior index date `` condition '' Patients dialysis [ 4 quarter prior index date ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban , Phenprocoumon , retrospective cohort study , Non-Valvular Atrial fibrillation , NVAF</keyword>
</DOC>